skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Global Generics & Biosimilars Awards 2021



2021 Shortlist Announced!

Winner teaser image

The Global Generics & Biosimilars Awards 2021 shortlist has been released!

Taking place November 10, 2021 at the Stella Polare, Fiera Milano, Milan, Italy, the Global Generics & Biosimilars Awards 2021 is the one night of the year when the off-patent pharmaceutical industry’s greatest achievements are put in the spotlight and will reward companies across the off-patent industry – including small-molecule generics, biosimilars and value-added medicines – by recognizing their successes over the past year.

Our awards categories crown the industry’s leading companies, both on a global and regional basis; highlight achievements in biosimilars and value-added medicines; and also recognize the industry’s biggest deals, regulatory milestones and company leaders.

API suppliers and other industry partners also have their own categories in which to compete for recognition, while companies are also presented with awards for their CSR activities, their intellectual property strategies and other business development initiatives.

As the world continues to grapple with the COVID-19 pandemic, there has perhaps never been a more appropriate time to recognize the ongoing efforts made by the worldwide off-patent industry to provide access to quality, effective medicines at affordable prices around the globe.



Key Dates:

Icons_Pharma_Trophy_SolidPink_RGBAwards Ceremony: November 10, 2021



Sponsored by:


Since its foundation in 2009, Pharmacloud has steadily built up its reputation as a provider of specialist advice and consultancy to both the pharma industry and financial investors. We offer a number of services, with a particular focus on commercial due diligence on off-patent products. However, we also work with big pharma companies on generic defence strategies, as well as with emerging pharma companies seeking to assess the potential market for their value-added generic products or biosimilars.

The research side of our business is currently being built up, starting from the base of our well-regarded industry blog. Look out for the first in our series of in-depth reports beginning in 2015.


Adalvo is a global pharmaceutical company, and one of the leading B2B pharmaceutical companies in Europe, with commercial partnerships in more than 70 countries and for over 90 commercial partners globally. The company’s declared purpose is to make a difference for patients all over the world, driven by our smart collaboration network and commitment to delivering highest quality differentiated products and services to our partners.

At Adalvo, we know that our partners like to be bigger, better and smarter in the dynamic pharmaceutical sector. That’s why our approach is unique, customised to our partners, and is designed to challenge the status quo: together, this helps our partners achieve their business goals. We take pride in our ability to help its partners reach their goals – be those increasing revenues or pushing into new markets.

Adalvo is also committed to its purpose and mission to accelerate the growth and development of employees and local communities. Adalvo tirelessly strives for excellence in all of its endeavours, driven by a deep-rooted passion to making a difference for partners and improve the lives of patients around the world.


Associate Sponsor:



Supported By:



In communities around the world affected by chronic poverty, conflict or disasters, easily treatable diseases can mean chronic pain, poor quality of life or even a death sentence. International Health Partners (IHP) was founded in 2003 with a vision to radically enhance access to medicine to the world’s most vulnerable people. IHP enable targeted donations of medicines from a network of over 60 healthcare companies across Europe, and coordinate the safe and responsible supply of these to disaster hit and vulnerable communities across the world.  IHP are the only organisation working to this model in the UK.  In the last three years IHP have sent over 8.2 million treatments, with a value of over £34.5 million.

Global Generics & Biosimilars testimonials

Accord Healthcare

Fantastic event, excitement and energy was high and the awards were flawless.

Avril Fudge

Hetero Europe

The Oscars for the Generics and Biosimilars industry!

Bjarni Baerings

Accord Healthcare

Well-run award ceremony that highlights the positive impact the off patent medicines sector has on society in general and health in particular.

James Burt


GGBA is absolutely a sensational event for the global pharma industry to be a part of it. Entire process of being  nominated, evaluated and assessed is exciting for the nominee. It also brings global pharma professionals together and exchange opportunities. I was the finalist  for "Leader of the Year" award and it was so rewarding in terms of learning from other finalist, from Sandoz, Accord Health, mAbxienceand Stada. I don't think I will ever be able to miss entering the awards in the years to come. It keeps me motivated entire year.

Nadeem Rehmat

Contact us today

For Sponsorship Opportunities contact:

Christopher Keeling
Tel: +44 (0) 7917 647 859

For all other inquiries:
Jo Kirkpatrick
Tel: +44 (0) 7917 555 986